Abstract
Sudden infant death syndrome (SIDS), the most common cause of infant death in developed countries, is attributed to diverse trigger factors. Malignant cardiac dysrhythmias are potentially treatable etiologies, and congenital long QT syndrome (LQTS) is the most common cardiac ionic channelopathy confronted. β-Blockers or class Ib agents are the drugs of choice for the control of arrhythmias, and an implantable cardioverter defibrillator (ICD) should be considered for secondary prevention in survivors of lethal cardiac death. We report the case of a 4-day old neonate, later genetically confirmed as LQT type 3 (LQT3), who survived a pulseless torsades de pointes (TdP) attack and was successfully treated with propranolol, mexiletine, and ICD implantation.
Original language | English |
---|---|
Article number | 184 |
Journal | Journal of Cardiovascular Development and Disease |
Volume | 9 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2022 |
Keywords
- implantable cardioverter defibrillator
- long QT syndrome
- sudden infant death syndrome
- torsades de pointes